PL3618928T3 - Przeciwciała antysortylinowe i sposoby ich stosowania - Google Patents

Przeciwciała antysortylinowe i sposoby ich stosowania

Info

Publication number
PL3618928T3
PL3618928T3 PL19746306.0T PL19746306T PL3618928T3 PL 3618928 T3 PL3618928 T3 PL 3618928T3 PL 19746306 T PL19746306 T PL 19746306T PL 3618928 T3 PL3618928 T3 PL 3618928T3
Authority
PL
Poland
Prior art keywords
methods
sortilin antibodies
sortilin
antibodies
Prior art date
Application number
PL19746306.0T
Other languages
English (en)
Inventor
Tina SCHWABE
Michael KURNELLAS
Arnon Rosenthal
Robert PEJCHAL
Anthony B. Cooper
Original Assignee
Alector Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alector Llc filed Critical Alector Llc
Publication of PL3618928T3 publication Critical patent/PL3618928T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
PL19746306.0T 2018-07-13 2019-07-12 Przeciwciała antysortylinowe i sposoby ich stosowania PL3618928T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862698007P 2018-07-13 2018-07-13
US201962860184P 2019-06-11 2019-06-11
US201962868849P 2019-06-28 2019-06-28
PCT/US2019/041614 WO2020014617A1 (en) 2018-07-13 2019-07-12 Anti-sortilin antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
PL3618928T3 true PL3618928T3 (pl) 2023-05-02

Family

ID=67480375

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19746306.0T PL3618928T3 (pl) 2018-07-13 2019-07-12 Przeciwciała antysortylinowe i sposoby ich stosowania

Country Status (29)

Country Link
US (3) US11396546B2 (pl)
EP (2) EP3618928B1 (pl)
JP (2) JP7208157B2 (pl)
KR (2) KR102530517B1 (pl)
CN (1) CN111372655A (pl)
AU (1) AU2019246837B2 (pl)
BR (1) BR112019022666A2 (pl)
CA (1) CA3060547A1 (pl)
CL (2) CL2021000089A1 (pl)
CO (1) CO2021001742A2 (pl)
CR (1) CR20210057A (pl)
DK (1) DK3618928T3 (pl)
EC (1) ECSP21010450A (pl)
ES (1) ES2940311T3 (pl)
FI (1) FI3618928T3 (pl)
HR (1) HRP20230344T1 (pl)
HU (1) HUE061841T2 (pl)
IL (1) IL270214B1 (pl)
LT (1) LT3618928T (pl)
MX (1) MX2019012869A (pl)
PE (1) PE20210186A1 (pl)
PH (1) PH12021550041A1 (pl)
PL (1) PL3618928T3 (pl)
PT (1) PT3618928T (pl)
RS (1) RS64034B1 (pl)
SI (1) SI3618928T1 (pl)
TW (1) TWI809147B (pl)
WO (1) WO2020014617A1 (pl)
ZA (1) ZA201906731B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201792221A1 (ru) 2015-04-07 2018-08-31 ЭЛЕКТОР ЭлЭлСи Антитела против сортилина и способы их применения
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) * 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
WO2020252066A1 (en) * 2019-06-11 2020-12-17 Alector Llc Anti-sortilin antibodies for use in therapy
AU2021362487A1 (en) 2020-10-14 2023-06-08 Denali Therapeutics Inc. Methods for treating and monitoring frontotemporal dementia
JP2023553399A (ja) * 2020-12-02 2023-12-21 アレクトル エルエルシー 抗ソルチリン抗体の使用法
CN112920264B (zh) * 2021-02-08 2022-07-05 武汉大学 Tdp-43蛋白的o-糖基化突变体及其应用
WO2023247754A1 (en) 2022-06-23 2023-12-28 Draupnir Bio Aps Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes
CN115281146B (zh) * 2022-07-08 2023-06-16 山东省农业科学院家禽研究所（山东省无特定病原鸡研究中心） 一种鸡湿热下利证模型的构建方法
CN116731169B (zh) * 2023-08-09 2023-11-03 瑞诺元(苏州)生物科技有限公司 一种分拣蛋白1特异性的纳米抗体及其应用

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
EP0308936B1 (en) 1987-09-23 1994-07-06 Bristol-Myers Squibb Company Antibody heteroconjugates for the killing of HIV-infected cells
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CA2507749C (en) 1991-12-13 2010-08-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
AU668423B2 (en) 1992-08-17 1996-05-02 Genentech Inc. Bispecific immunoadhesins
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
JP2002514895A (ja) 1995-09-28 2002-05-21 アレクション、ファーマスーティカルズ、インコーポレーテッド ブタ細胞相互作用タンパク質
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
MXPA02003456A (es) 1999-10-04 2002-10-23 Medicago Inc Metodo para regular la transcripcion de genes foraneos.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101940189A (zh) 2000-11-30 2011-01-12 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
JP2006504971A (ja) 2002-11-01 2006-02-09 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト マトリックス支援レーザー脱離イオン化−飛行時間型質量分析によるタンパク質アイソフォームの定量的解析
EP1589988A2 (en) 2002-12-20 2005-11-02 Neuronicon ApS Modulation of activity of neurotrophins
WO2005044293A2 (en) 2003-11-07 2005-05-19 Lay Line Genomics S.P.A. Compositions able to prevent neurodegenerative processes and methods of assaying the same
JP5128935B2 (ja) 2004-03-31 2013-01-23 ジェネンテック， インコーポレイテッド ヒト化抗ＴＧＦ−β抗体
AP2007004034A0 (en) 2004-12-31 2007-06-30 Genentech Inc Polypeptides sthat bind br3 and uses thereof
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
US8877714B2 (en) 2005-06-14 2014-11-04 Raptor Pharmaceutical Inc. Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof
EP1907424B1 (en) 2005-07-01 2015-07-29 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EP1945240B1 (en) 2005-09-16 2016-12-28 Raptor Pharmaceutical Inc Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
FR2896881B1 (fr) 2006-01-31 2008-04-18 Biomerieux Sa Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie
EP2001490A1 (en) 2006-03-15 2008-12-17 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
CA2663377A1 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
WO2008052016A2 (en) 2006-10-23 2008-05-02 Columbia University The sortilin-related receptor sorl1 is functionally and genetically associated with alzheimer's disease
WO2008076262A2 (en) 2006-12-15 2008-06-26 Merck & Co., Inc. Receptor for amyloid beta and uses thereof
EP2120997B1 (en) 2006-12-21 2017-03-01 H. Lundbeck A/S Modulation of activity of proneurotrophins
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
WO2008086452A2 (en) 2007-01-10 2008-07-17 Columbia University Treatment and prevention of alzheimer's disease
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
CL2008002153A1 (es) * 2007-07-24 2009-06-05 Amgen Inc Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
AU2008298603B2 (en) 2007-09-14 2015-04-30 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8592562B2 (en) 2008-01-07 2013-11-26 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
EP2274327B1 (en) 2008-04-27 2019-03-27 H. Lundbeck A/S Crystal structure of human sortilin and uses thereof for identifying ligands to sortilin
US20160359907A1 (en) 2015-06-02 2016-12-08 Vmware, Inc. Automatically auditing virtual machines for security hardening compliance
ES2680222T3 (es) 2008-05-22 2018-09-05 H. Lundbeck A/S Modulación de los receptores con dominio Vps10p para el tratamiento de la enfermedad cardiovascular
DK2732823T3 (da) 2008-06-25 2019-09-16 H Lundbeck As Modulering af TrpV : Vps10p-domæne-receptorsystemet til behandlingen af smerte
CN103980363B (zh) 2008-07-16 2017-04-12 生物医学研究学会 人巨细胞病毒中和抗体及其应用
WO2010022175A1 (en) 2008-08-19 2010-02-25 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
US20110270275A1 (en) 2008-09-08 2011-11-03 Mayo Foundation For Medical Education And Research Methods and devices for ligating tubular structures
EP2379593A2 (en) 2008-12-19 2011-10-26 H. Lundbeck A/S Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
CA2774998A1 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
CN103228295B (zh) 2010-06-15 2015-06-24 康奈尔大学 一种限制急性心肌缺血后微血管损伤的方法
DK2593594T3 (en) 2010-07-16 2017-12-11 Adimab Llc ANTIBODY LIBRARIES
WO2012068332A2 (en) 2010-11-17 2012-05-24 Cornell University Methods for treating early stage or mild neurological disorders
CN103649123B (zh) 2011-06-13 2017-05-24 Csl有限公司 抗g‑csfr抗体及其用途
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
JP6239635B2 (ja) 2012-11-02 2017-11-29 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 血管石灰化の誘導因子であるソルチリン１
EP2991679A4 (en) 2013-04-29 2016-12-07 Adimab Llc POLYSPECIFIC REAGENTS, PROCESS FOR THEIR PREPARATION AND USE
SG10201710758PA (en) 2013-07-09 2018-02-27 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
AU2015214358A1 (en) 2014-02-04 2016-08-18 New York University Progranulin (PGRN) and its derivatives for diagnosis and treatment of lysosomal storage diseases
JP2017508144A (ja) 2014-02-12 2017-03-23 ハー・ルンドベック・アクチエゼルスカベット 感情／気分障害のバイオマーカーとしてのソルチリンの使用
US20170096486A1 (en) 2014-03-26 2017-04-06 Goran Landberg Agents inhibiting granulin for treatment of cancer
EP3193942B1 (en) 2014-08-11 2020-03-25 Shire Human Genetic Therapies, Inc. Lysosomal targeting and uses thereof
US10849992B1 (en) 2015-04-07 2020-12-01 Alector Llc Methods of screening for sortilin binding antagonists
EA201792221A1 (ru) 2015-04-07 2018-08-31 ЭЛЕКТОР ЭлЭлСи Антитела против сортилина и способы их применения
US20160331746A1 (en) 2015-05-12 2016-11-17 University Of South Florida Sortilin-Binding Small Molecules for Increasing Glucose Uptake
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
WO2017024137A1 (en) 2015-08-04 2017-02-09 New York University Progranulin (pgrn) fragments and derivatives for treatment or alleviation of lysosomal storage diseases
US10085969B1 (en) 2016-02-12 2018-10-02 University Of South Florida Sortilin binding compounds, formulations, and uses thereof
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
US11833187B2 (en) 2017-10-23 2023-12-05 The Brigham And Women's Hospital, Inc. Materials and methods for extracellular vessicle-associated diseases
EP3807322A1 (en) 2018-06-18 2021-04-21 Denali Therapeutics Inc. Fusion proteins comprising progranulin
AU2019324747A1 (en) 2018-08-24 2021-04-01 Transfert Plus, S.E.C. Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry
WO2020051624A1 (en) 2018-09-11 2020-03-19 Grophin Pty Ltd Methods and compositions for improving recovery from a brain injury
EP3666281A1 (en) 2018-12-14 2020-06-17 Insusense ApS Compositions comprising sortilin-1
EP3942049A4 (en) 2019-03-20 2023-10-18 President And Fellows Of Harvard College PROGRANULIN AUGMENTATION THERAPY BASED ON ANTI-SENSE OLIGONUCLEOTIDES IN NEURODEGENERATIVE DISEASES
WO2020252066A1 (en) 2019-06-11 2020-12-17 Alector Llc Anti-sortilin antibodies for use in therapy

Also Published As

Publication number Publication date
AU2019246837B2 (en) 2024-03-21
CL2021000089A1 (es) 2021-07-02
US11396546B2 (en) 2022-07-26
BR112019022666A2 (pt) 2020-09-01
DK3618928T3 (da) 2023-03-27
ES2940311T3 (es) 2023-05-05
JP2023036932A (ja) 2023-03-14
TWI809147B (zh) 2023-07-21
CR20210057A (es) 2021-03-22
HRP20230344T1 (hr) 2023-06-09
WO2020014617A1 (en) 2020-01-16
CA3060547A1 (en) 2020-01-13
EP4212210A1 (en) 2023-07-19
PH12021550041A1 (en) 2021-09-20
IL270214A (en) 2020-01-30
JP7208157B2 (ja) 2023-01-18
IL270214B1 (en) 2024-03-01
CO2021001742A2 (es) 2021-03-08
LT3618928T (lt) 2023-04-11
RS64034B1 (sr) 2023-04-28
EP3618928B1 (en) 2023-01-18
US20230047941A1 (en) 2023-02-16
US20200024348A1 (en) 2020-01-23
KR102530517B1 (ko) 2023-05-09
JP2021530960A (ja) 2021-11-18
ZA201906731B (en) 2023-04-26
KR20230065382A (ko) 2023-05-11
US20220348656A1 (en) 2022-11-03
KR20210030185A (ko) 2021-03-17
ECSP21010450A (es) 2021-03-31
PT3618928T (pt) 2023-03-29
PE20210186A1 (es) 2021-02-02
SI3618928T1 (sl) 2023-04-28
TW202035450A (zh) 2020-10-01
AU2019246837A1 (en) 2020-01-30
FI3618928T3 (fi) 2023-04-21
EP3618928A1 (en) 2020-03-11
MX2019012869A (es) 2020-01-23
HUE061841T2 (hu) 2023-08-28
CN111372655A (zh) 2020-07-03
CL2021003327A1 (es) 2022-09-30

Similar Documents

Publication Publication Date Title
IL276731A (en) Antibodies against CD73 and methods of using them
SG11202010909RA (en) Anti-msr1 antibodies and methods of use thereof
PL3618863T3 (pl) Przeciwciała anty- tigit i sposoby ich zastosowania
ZA201906730B (en) Anti-trem2 antibodies and methods of use thereof
IL278821A (en) Anti-SIRPA antibodies and methods of using them
IL270214A (en) Anti-sortilin antibodies and methods of using them
IL279648A (en) Anti-SIRP-in-cell 1 antibodies and methods of using them
IL277212A (en) Anti-KLK5 antibodies and methods of use
IL290741A (en) Antibodies against cd-96 and methods of using them
SG11202108734VA (en) Anti-trem2 antibodies and methods of use thereof
IL287282A (en) Anti-mertk antibodies and methods of using them
IL283884A (en) Antibodies against il-36 and methods of using them
IL280338A (en) Anti-SIGLEC-5 antibodies and methods of using them
IL289952A (en) Anti-ms4a4a antibodies and methods of using them
IL285401A (en) Anti-clec2d antibodies and methods of using them
IL274221A (en) Antibodies to ANTI-APOC3 and methods of use
IL291461A (en) Anti-alpha-synuclein antibodies and methods of using them
IL279227A (en) Anti-SIGLEC-7 antibodies and methods of using them
EP4061848A4 (en) ANTI-ROR-2 ANTIBODIES AND METHODS OF USE
IL274376A (en) Antibodies and methods of use
IL288886A (en) Antibodies and methods of use